Hydrocortisone-loaded poly(ε-caprolactone) nanoparticles for atopic dermatitis treatment

Pharmaceutical Development and Technology

Volumn 18, Issue 3, 2013, Pages 710-718

  Rosado, Catarina ^a   Silva, Catarina ^a   Reis, Catarina P ^a  

^a UNIVERSIDADE LUSÓFONA DE HUMANIDADES E TECNOLOGIAS   (Portugal)

Author keywords

Atopic dermatitis; hydrocortisone acetate; nanoparticles; poly( caprolactone); prolonged drug release

Indexed keywords

DRUG CARRIER; HYDROCORTISONE; NANOPARTICLE; POLYCAPROLACTONE; POLYESTER;

CELL SURVIVAL; CHEMISTRY; DERMATITIS, ATOPIC; DRUG EFFECTS; HUMAN; MICROBIOLOGY; PATHOLOGY; PHYSIOLOGY; SACCHAROMYCES CEREVISIAE; SYNTHESIS; TREATMENT OUTCOME; ARTICLE; ATOPIC DERMATITIS; DRUG EFFECT;

CELL SURVIVAL; DERMATITIS, ATOPIC; DRUG CARRIERS; HUMANS; HYDROCORTISONE; NANOPARTICLES; POLYESTERS; SACCHAROMYCES CEREVISIAE; TREATMENT OUTCOME;

EID: 84891641274     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2012.712537     Document Type: Article

References (60)

1. Buys LM. Treatment options for atopic dermatitis. Am Fam Physician 2007; 75: 523 – 528.
2. Guttman-Yassky E, Nograles KE, Krueger JG. Contrasting pathogenesis of atopic dermatitis and psoriasis–part I: clinical and pathologic concepts. J Allergy Clin Immunol 2011; 127: 1110 – 1118.
3. Del Rosso JQ, Bhambri S. Daily application of fluocinonide 0.1% cream for the treatment of atopic dermatitis. J Clin Aesthet Dermatol 2009; 2: 24 – 32.
4. Meireles C, Hergy F, Mousinho MC, Afonso S, Rosado C. Characteristics of infantile skin of the cosmetic products formulated for this age group. Rev Lusófona de Ciências e Tecnologias da Saúde 2007; 4: 73 – 80.
5. Novak N, Leung DY. Advances in atopic dermatitis. Curr Opin Immunol 2011; 23: 778 – 783.
6. Atherton DJ. Topical corticosteroids in atopic dermatitis. BMJ 2003; 327: 942 – 943.
7. Ference JD, Last AR. Choosing topical corticosteroids. Am Fam Physician 2009; 79: 135 – 140.
8. Pinto Reis C, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems. Nanomedicine 2006; 2: 53 – 65.
9. Bhowmik D, Chiranjib, Chandira RM, Jayakar B. Role of nanotechnology in novel drug delivery system. JPST 2009; 1: 20 – 35.
10. Hughes GA. Nanostructure-mediated drug delivery. Nanomedicine 2005; 1: 22 – 30.
11. Chen H, Chang X, Du D, Li J, Xu H, Yang X. Microemulsion-based hydrogel formulation of ibuprofen for topical delivery. Int J Pharm 2006; 315: 52 – 58.
12. Couvreur P, Puisieux F. Nano- and microparticles for the delivery of polypeptides and proteins. Adv Drug Deliv Rev 1993; 10: 141 – 162.
13. Hans ML, Lowman AM. Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mater Sci 2002; 6: 319 – 327.
14. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces 2010; 75: 1 – 18.
15. Sinha VR, Bansal K, Kaushik R, Kumria R, Trehan A. Poly-epsilon-caprolactone microspheres and nanospheres: an overview. Int J Pharm 2004; 278: 1 – 23.
16. Alvarez-Román R, Naik A, Kalia YN, Guy RH, Fessi H. Enhancement of topical delivery from biodegradable nanoparticles. Pharm Res 2004; 21: 1818 – 1825.
17. Ourique AF, Melero A, de Bona da Silva C, Schaefer UF, Pohlmann AR, Guterres SS et al. Improved photostability and reduced skin permeation of tretinoin: development of a semisolid nanomedicine. Eur J Pharm Biopharm 2011; 79: 95 – 101.
18. Pinto Reis C, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine 2006; 2: 8 – 21.
19. Nara S, Tripathi V, Singh H, Shrivastav TG. Colloidal gold probe based rapid immunochromatographic strip assay for cortisol. Anal Chim Acta 2010; 682: 66 – 71.
20. Boddu SH, Jwala J, Vaishya R, Earla R, Karla PK, Pal D et al. Novel nanoparticulate gel formulations of steroids for the treatment of macular edema. J Ocul Pharmacol Ther 2010; 26: 37 – 48.
21. Cavalli R, Peira E, Caputo O, Gasco MR. Solid lipid nanoparticles as carriers of hydrocortisone and progesterone complexes with beta-cyclodextrins. Int J Pharm 1999; 182: 59 – 69.
22. Jensen LB, Magnussson E, Gunnarsson L, Vermehren C, Nielsen HM, Petersson K. Corticosteroid solubility and lipid polarity control release from solid lipid nanoparticles. Int J Pharm 2010; 390: 53 – 60.
23. Vandervoort J, Ludwig A. Preparation and evaluation of drug-loaded gelatin nanoparticles for topical ophthalmic use. Eur J Pharm Biopharm 2004; 57: 251 – 261.
24. Lee CM, Lim S, Kim GY, Kim DW, Rhee JH, Lee KY. Rosin nanoparticles as a drug delivery carrier for the controlled release of hydrocortisone. Biotechnol Lett 2005; 27: 1487 – 1490.
25. Rosado C, Silva C, Reis CP. Hydrocortisone nanoparticles for atopic dermatitis treatment. SOFW J 2011; 137: 2 – 7.
26. Jenning V, Gysler A, Schäfer-Korting M, Gohla SH. Vitamin A loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin. Eur J Pharm Biopharm 2000; 49: 211 – 218.
27. Pople PV, Singh KK. Targeting tacrolimus to deeper layers of skin with improved safety for treatment of atopic dermatitis. Int J Pharm 2010; 398: 165 – 178.
28. Brown KK, Rehmus WE, Kimball AB. Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis. J Am Acad Dermatol 2006; 55: 607 – 613.
29. Brown KL, Krejci-Manwaring J, Tusa MG, Camacho F, Fleischer AB Jr, Balkrishnan R et al. Poor compliance with topical corticosteroids for atopic dermatitis despite severe disease. Dermatol Online J 2008; 14: 13.
30. Gelbard CM, Hebert AA. New and emerging trends in the treatment of atopic dermatitis. Patient Prefer Adherence 2008; 2: 387 – 392.
31. Jetzer WE, Huq AS, Ho NF, Flynn GL, Duraiswamy N, Condie L Jr. Permeation of mouse skin and silicone rubber membranes by phenols: relationship to in vitro partitioning. J Pharm Sci 1986; 75: 1098 – 1103.
32. Twist JN, Zatz JL. (1986). Influence of solvents on paraben permeation through idealised skin model membranes. J Soc Cosm Chem 37: 429 – 444.
33. Gelotte KM, Lostritto RT. Solvent interaction with polydimethylsiloxane membranes and its effects on benzocaine solubility and diffusion. Pharm Res 1990; 7: 523 – 529.
34. Buschini A, Poli P, Rossi C. Saccharomyces cerevisiae as an eukaryotic cell model to assess cytotoxicity and genotoxicity of three anticancer anthraquinones. Mutagenesis 2003; 18: 25 – 36.
35. Marrot L, Labarussiat A, Perez P, Meunier JR. Use of the yeast Saccharomyces cerevisiae as a pre-screening approach for assessment of chemical-induced phototoxicity. Toxicol In Vitro 2006; 20: 1040 – 1050.
36. Roberto A, Caetano PP. A high-throughput screening method for general cytotoxicity. Part I: chemical toxcity. Rev Lusófona de Ciências e Tecnologias da Saúde 2005; 2: 95 – 100.
37. Al-Kassas RS, Al-Gohary OM, Al-Faadhel MM. Controlling of systemic absorption of gliclazide through incorporation into alginate beads. Int J Pharm 2007; 341: 230 – 237.
38. Törmä H, Lindberg M, Berne B. Skin barrier disruption by sodium lauryl sulfate-exposure alters the expressions of involucrin, transglutaminase 1, profilaggrin, and kallikreins during the repair phase in human skin in vivo. J Invest Dermatol 2008; 128: 1212 – 1219.
39. Rosado C, Lourenço A, Rodrigues LM. Assessment of the impact of a cream containing urea in skin barrier function. Rev Lusófona de Ciências e Tecnologias da Saúde 2008; 2: 166 – 173.
40. Hammady T, El-Gindy A, Lejmi E, Dhanikula RS, Moreau P, Hildgen P. Characteristics and properties of nanospheres co-loaded with lipophilic and hydrophilic drug models. Int J Pharm 2009; 369: 185 – 195.
41. Layre AM, Gref R, Richard J, Requier D, Chacun H, Appel M et al. Nanoencapsulation of a crystalline drug. Int J Pharm 2005; 298: 323 – 327.
42. Musumeci T, Ventura CA, Giannone I, Ruozi B, Montenegro L, Pignatello R et al. PLA/PLGA nanoparticles for sustained release of docetaxel. Int J Pharm 2006; 325: 172 – 179.
43. Raiman J, Hänninen K, Kontturi K, Murtomäki L, Hirvonen J. Drug adsorption in human skin: a streaming potential study. J Pharm Sci 2003; 92: 2366 – 2372.
44. Desai P, Patlolla RR, Singh M. Interaction of nanoparticles and cell-penetrating peptides with skin for transdermal drug delivery. Mol Membr Biol 2010; 27: 247 – 259.
45. Baroli B. Penetration of nanoparticles and nanomaterials in the skin: fiction or reality? J Pharm Sci 2010; 99: 21 – 50.
46. Morykwas MJ, Thornton JW, Bartlett RH. Zeta potential of synthetic and biological skin substitutes: effects on initial adherence. Plast Reconstr Surg 1987; 79: 732 – 739.
47. Jung S, Otberg N, Thiede G, Richter H, Sterry W, Panzner S et al. Innovative liposomes as a transfollicular drug delivery system: penetration into porcine hair follicles. J Invest Dermatol 2006; 126: 1728 – 1732.
48. Kohli AK, Alpar HO. Potential use of nanoparticles for transcutaneous vaccine delivery: effect of particle size and charge. Int J Pharm 2004; 275: 13 – 17.
49. Prow TW, Grice JE, Lin LL, Faye R, Butler M, Becker W et al. Nanoparticles and microparticles for skin drug delivery. Adv Drug Deliv Rev 2011; 63: 470 – 491.
50. Liang CH, Chou TH. Effect of chain length on physicochemical properties and cytotoxicity of cationic vesicles composed of phosphatidylcholines and dialkyldimethylammonium bromides. Chem Phys Lipids 2009; 158: 81 – 90.
51. Okada S, Hiroshige R, Tanaka M, Murai M, Kimura T. [Hydrocortisone Acetate Reference Standard (Control 891) of National Institute of Hygienic Sciences]. Eisei Shikenjo Hokoku 1990; 108:147 – 149.
52. Raghavan SL, Kiepfer B, Davis AF, Kazarian SG, Hadgraft J. Membrane transport of hydrocortisone acetate from supersaturated solutions; the role of polymers. Int J Pharm 2001; 221: 95 – 105.
53. Verma D, Katti K, Katti D. Experimental investigation of interfaces in hydroxyapatite/polyacrylic acid/polycaprolactone composites using photoacoustic FTIR spectroscopy. J Biomed Mater Res A 2006; 77: 59 – 66.
54. Vogel C, Wessel E, Siesler HW. FT-IR imaging spectroscopy of phase separation in blends of poly(3-hydroxybutyrate) with poly(L-lactic acid) and poly(epsilon-caprolactone). Biomacromolecules 2008; 9: 523 – 527.
55. Medina C, Santos-Martinez MJ, Radomski A, Corrigan OI, Radomski MW. Nanoparticles: pharmacological and toxicological significance. Br J Pharmacol 2007; 150: 552 – 558.
56. Hoetzenecker W, Meingassner JG, Ecker R, Stingl G, Stuetz A, Elbe-Bürger A. Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. J Invest Dermatol 2004; 122: 673 – 684.
57. Komine M. Analysis of the mechanism for the development of allergic skin inflammation and the application for its treatment:keratinocytes in atopic dermatitis - their pathogenic involvement. J Pharmacol Sci 2009; 110: 260 – 264.
58. Le Ray AM, Chiffoleau S, Iooss P, Grimandi G, Gouyette A, Daculsi G et al. Vancomycin encapsulation in biodegradable poly(epsilon-caprolactone) microparticles for bone implantation. Influence of the formulation process on size, drug loading, in vitro release and cytocompatibility. Biomaterials 2003; 24: 443 – 449.
59. Chawla JS, Amiji MM. Biodegradable poly(epsilon -caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen. Int J Pharm 2002; 249: 127 – 138.
60. De Jong WH, Borm PJ. Drug delivery and nanoparticles:applications and hazards. Int J Nanomedicine 2008; 3: 133 – 149.